BioMarin faces make-or-break FDA panel vote; Ackman re-ups his Valeant stake;

@FierceBiotech: Genmab's lymphoma project flops in Phase III with Novartis holding the bag. Article | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our  breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

@DamianFierce: Has anyone asked the presumptive FDA chief whether jet fuel can melt steel? More | Follow @DamianFierce

> BioMarin ($BMRN) is in the midst of a make-or-break meeting with FDA advisers over its in-development treatment for Duchenne muscular dystrophy. The Street's Adam Feuerstein is live-blogging the daylong discussion. More

> Bill Ackman, long a vocal supporter of the embattled Valeant Pharmaceuticals ($VRX), has acquired an even greater stake in the company. More

> Array BioPharma's ($ARRY) chief financial officer is stepping down after four months on the job. News

Medical Device News

@FierceMedDev: Startup gets $36.5M to conduct U.S. pivotal trial for novel endoscopic weight loss device. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: Dell teams up with Zebra Medical Vision for data analytics initiative. Report | Follow @EmilyWFierce

> Dell teams up with Zebra Medical Vision for data analytics initiative. Story

> Cigna launches genetic counseling program for hereditary cancers. Article

Pharma News

@FiercePharma: Japan's Takeda gets early U.S. FDA nod for ixazomib. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: ICYMI: Catalent halts production, calls authorities into French plant where tampering is suspected. Article | Follow @EricPFierce

@CarlyHFierce: With veteran job-choppers Pfizer and Allergan joining hands, how many layoffs are in the cards? More | Follow @CarlyHFierce

> Trump, Clinton lash out at Pfizer over Allergan deal agreement. More

> Forget Pfizer and Allergan, Teva is the pharma getting the most market love these days. Report

> JAMA: Gilead, AbbVie hep C meds cost-effective even in early stages of liver disease. Article

Drug Delivery News

> Depomed acquires pain candidate for $25M as it fends off Horizon's hostile takeover. Item

> AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate. More

> J&J leads $24M financing into maker of OTC 'liquid shots' for common ailments. Report

> Pills loaded with mucoadhesive patches could make oral insulin a reality. Story

> Adapt Pharma earns FDA approval of first intranasal spray for emergency opioid overdose. Article

Pharma Manufacturing News

> Novo Nordisk says all its manufacturing plants will run on renewable electricity by 2020. News

> Abzena to raise $30M to buy another U.S. contract drug developer. Report

> Some production resumes at Strides Shasun facility following fire that killed one. More

> Synerlab buys contract manufacturing developer Alcala Farma for undisclosed price. Story

> South Africa's Ascendis picks up manufacturing facility in $24.6M deal for Akacia. Article

Pharma Asia News

> India's Biocon chief says R&D tax breaks essential for investment. Story

> China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi. More

> India's gliptin market ready for a shakeup by Zydus at 11 U.S. cents a pill. Report

> Japan's Takeda gets early U.S. FDA nod for ixazomib. Item

> India-EU trade talks back on next year, GVK issue sidelined. Article

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.